UK R&D firm Futura Medical has cleared the first hurdle on the way to gaining US Food and Drug Administration approval for its drug-free erectile dysfunction gel MED3000 as an OTC medical device.
Study Suggests Futura’s Drug-Free Erectile Dysfunction Gel Suitable For US OTC Pathway
The successful completion of a short, non-clinical, human factors study puts Futura Medical's MED3000 erectile dysfunction gel one step closer to OTC device approval in the US.
More from Regulation
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.
• By
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.
• By
Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.